Cure8 research brief
The work identifies factors that predict loss of response to infliximab and suggests maintenance drug levels are the strongest predictor, which could influence monitoring strategies for people with Crohn's disease on infliximab.
Patients on infliximab, gastroenterologists/IBD clinicians, and researchers working on biomarkers or AI prognostic models.
Researchers retrospectively analyzed 637 Crohn's patients starting infliximab and compared several time-to-event ML models. A gradient boosting machine performed best, with better discrimination at longer follow-up (24–36 months) than at 12 months.
Key predictors included maintenance IFX trough levels, disease duration, induction-phase anti-drug antibodies, platelet count, sex, concomitant immunosuppressant use, and white blood cell count.
The authors used SurvSHAP to make the model more interpretable and found maintenance troughs had the largest effect range; concomitant immunosuppressants showed a protective signal. The study is internally validated but limited to a single-center retrospective cohort, and the authors call for external multicenter validation before clinical implementation.
This report is an internally validated, retrospective single-center study (abstract/full-text level). External multicenter validation is needed before applying the model in routine care. The 12-month predictive performance was modest compared with later time points.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
